GaryDubinMD

Internal Medicine • West Chester, PA

Infectious Disease

Physician

Join to view full profile

Dr. Dubin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dubin's full profile

Already have an account?

Office
1549 Tanglewood Dr
West Chester, PA 19380
Phone+1 610-651-0827

Education & Training

University of Pennsylvania Health SystemFellowship, Infectious Disease, 1989 - 1991
University of ColoradoResidency, Internal Medicine, 1983 - 1986
Perelman School of Medicine at the University of PennsylvaniaClass of 1983

Certifications & Licensure

PA State Medical License 1987 - 2026
CO State Medical License 1985 - 1989
American Board of Internal Medicine Internal Medicine

Publications & Presentations

PubMed

5 citations
Serologic response to porcine circovirus type 1 (PCV1) in infants vaccinated with the human rotavirus vaccine, Rotarix™: A retrospective laboratory analysis
Htay Htay Han, Naveen Karkada, Girish Jayadeva, Gary Dubin
Human Vaccines & Immunotherapeutics. 2017-01-02
69 citations
Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-h...
Suzanne M. Garland, Jorma Paavonen, Unnop Jaisamrarn, Paulo Naud, Jorge Salmerón
International Journal of Cancer. 2016-12-15
21 citations
Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12–15 years: Interim analysis of a large community-randomized controlled trial
Matti Lehtinen, Tiina Eriksson, Dan Apter, Mari Hokkanen, Kari Natunen
Human Vaccines & Immunotherapeutics. 2016-11-14

Press Mentions

Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union | Pages DaDecember 8th, 2022
Takeda Dengue Vaccine Recommended for Approval by European CommitteeOctober 17th, 2022
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic CountriesOctober 14th, 2022